Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 18

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 18
---
,                                                                                              
 acquire, license, and/or develop other product candidates and subsequent generations of our current product candidate; |
| ● | seek to maintain, protect,                                                                                             
 and expand our intellectual property portfolio;                                                                        |

<div align='center'>14</div>

| ● | seek to attract and retain skilled personnel;                                                                                        |
| ● | create additional infrastructure                                                                                                     
 to support our operations as a public company and our product candidate development and planned future commercialization efforts;    
 and                                                                                                                                  |
| ● | experience any delays or                                                                                                             
 encounter issues with respect to any of the above, including, but not limited to, failed studies, complex results, safety issues     
 or other regulatory challenges that require longer follow-up of existing studies or additional supportive studies in order to pursue 
 marketing approval.                                                                                                                  |

The
amount of any future operating losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding
through equity or debt financings, strategic collaborations or grants. Even if we obtain additional regulatory approvals to market our
Gelrin products and product candidates or any future product candidates, our future revenue will depend upon the size of any markets
in which our products and product candidates receive approval and our ability to achieve sufficient market acceptance, pricing, reimbursement
from third-party payors for our products and product candidates. Further, the operating losses that we incur may fluctuate significantly
from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication
of our future performance. Other unanticipated costs may also arise.

We have not generated any revenue from product sales and may never be profitable.

While
our GelrinC has been approved as a device with a CE mark in Europe since August 2017, we have not yet begun to commercialize our products
and have never generated any revenue from product sales. Our ability to generate revenue and achieve profitability mainly depends on
our ability to find a marketing partner for Europe after we scale-up our manufacturing and prepare our GelrinC product for launch. In
parallel, we need to receive the necessary regulatory approvals to commercialize our GelrinC in the United States. We do not know when,
or if at all, we will generate any such revenue. Our ability to generate future revenue from product sales will depend heavily on our
success in many areas, including but not limited to:

| ● | complete research and development                                                                    
 of our Gelrin hydrogel platform and any future product candidates